BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Sickle cell disease clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for sickle cell disease: 42 (25 sponsors; 2 newly posted in the last 180 days, 3 stopped in the last 180 days; 1 new-entrant sponsors). Momentum score 15.5, rank 42 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 1, Phase 1 3, Phase 2 13, Phase 3 15, Phase 4 2, N/A 8.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Vertex Pharmaceuticals Incorporated VERX3P3 300
Novartis Pharmaceuticals NVS5P4 1, P1 1, P2 1, P3 200
Agios Pharmaceuticals, Inc. AGIO4P4 1, P3 2, P2 110
Novo Nordisk A/S NVO2P3 200
Sanofi SNY2P3 201
Forma Therapeutics, Inc.3P2 2, P3 100
Genetix Biotherapeutics Inc.2NA 1, P3 101
Asklepion Pharmaceuticals, LLC1P3 100
Pfizer PFE1P3 100
Beam Therapeutics Inc. BEAM2P2 1, NA 100
CSL Behring2P2 200
Editas Medicine, Inc. EDIT2NA 1, P2 100
Axiom Bioregistry new entrant1NA 110
Biossil Inc.1P2 100
Bristol-Myers Squibb BMY1P2 101
CorrectSequence Therapeutics Co., Ltd1EARLY_P1 101
Disc Medicine, Inc IRON1P1 100
EpiDestiny, Inc.1P1 100
Hemanext1NA 100
Imara, Inc.1P2 100
Kamau Therapeutics1P2 101
Nova Laboratories Limited NVMI1NA 100
Ossium Health, Inc.1NA 100
Sangamo Therapeutics SGMOQ1NA 100
Theravia1P2 100

New-entrant sponsors: Axiom Bioregistry.

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12-31 est.P1/P2Kamau TherapeuticsNCT04819841 Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell DiseaseSickle Cell Diseaserecruiting15
2027-01-06 est.P1/P2Bristol-Myers Squibb BMYNCT06481306 A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell DiseaseAnemia, Sickle Cell; Healthy Volunteersrecruiting224
2027-01-07 est.P3Sanofi SNYNCT07247188 Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell DiseaseSickle Cell Diseaserecruiting100

FDA decision events (last 12 months and upcoming)

DateEventStatusCompanyDrugSource
2026-09-30PDUFA date (company-disclosed)date passedAGIOS PHARMACEUTICALS, INC. AGIOPDUFA September 30, 2026 - AGIOS PHARMACEUTICALS, INC.

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-09-30 est.P2Cerus Corporation CERSNCT07155031 Biotin-Acridine Red Cell Exchange KineticsSickle Cell Diseasewithdrawn
2026-06-30P2Hillhurst Biopharmaceuticals, Inc.NCT06144749 A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)Anemia, Sickle Cellcompleted13
2026-06-04P2Fulcrum Therapeutics FULCNCT07401823 Open-Label Extension Study to Pioneer Study 6058-SCD-101Sickle Cell Diseaseterminated1

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "sickle cell disease"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.